4basebio PLC (LON:4BB - Get Free Report) traded up 1.8% during trading on Monday . The company traded as high as GBX 1,140 ($14.38) and last traded at GBX 1,140 ($14.38). 9 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 845 shares. The stock had previously closed at GBX 1,120 ($14.13).
The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The company has a market cap of £146.03 million, a price-to-earnings ratio of -1,461.54 and a beta of 1.09. The firm has a 50 day moving average price of GBX 1,190.30 and a two-hundred day moving average price of GBX 1,295.99.
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider 4basebio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4basebio wasn't on the list.
While 4basebio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.